SUBSTANCE-INDUCED PSYCHOSIS LINKED TO BOTH INFECTIONS AND SCHIZOPHRENIA by Hjorthoj, Carsten et al.
u n i ve r s i t y  o f  co pe n h ag e n  
SUBSTANCE-INDUCED PSYCHOSIS LINKED TO BOTH INFECTIONS AND
SCHIZOPHRENIA
Hjorthoj, Carsten; Starzer, Marie; Benros, Michael; Nordentoft, Merete
DOI:
10.1093/schbul/sbaa029.643
Publication date:
2020
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Hjorthoj, C., Starzer, M., Benros, M., & Nordentoft, M. (2020). SUBSTANCE-INDUCED PSYCHOSIS LINKED
TO BOTH INFECTIONS AND SCHIZOPHRENIA. S263. Abstract from Congress of the Schizophrenia-
International-Research-Society (SRIS), Florence, Italy. https://doi.org/10.1093/schbul/sbaa029.643
Download date: 10. Sep. 2020
SIRS 2020 Abstracts
Poster Session III  S263
factors with preadult multiple drug use (p = 1.12 x 10^-25, OR = 243.6). 
Furthermore, preadult environmental risk accumulation strongly 
predicted onset of  multiple drug use in adulthood (> 18 years; p = 6.27 
x 10^-18, OR  =  19.4). The application of  the novel genetic approach 
yielded 35 single-nucleotide variants (SNPs) that potentially confer sus-
ceptibility to preadult multiple drug use. Out of  these, 14 were located 
in gene-coding regions. Interestingly, 9 of  these genes are implicated in 
neuronal development/function or metabolite transport/transformation. 
Additional gene-based analyses identified another 4 genes relevant for 
metabolite transport/transformation as well as 4 genes that play a role in 
hypoxia signaling.
Discussion: The present results show that an accumulation of environmental 
risk factors during early life (< 18 years) is a strong predictor of multiple 
drug use during adolescence and later life. These findings suggest that ex-
posure to accumulated environmental risk during early life is not only as-
sociated with violent aggression – as previously reported by our lab – but is 
also an important predictor of multiple drug use. Moreover, we present first 
evidence of a genetic susceptibility to preadult multiple drug use, which will 
benefit from future replication in suitable samples of patients with mental 
illness or the general population.
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Background: Schizophrenia, schizoaffective disorder and bipolar affective 
disorder are associated with a life expectancy at birth that is 10–20 years 
shorter than in the general population. The prevalence of cigarette smoking 
in people with these disorders is very high, but the extent to which this 
accounts for differences in mortality is unclear. We addressed this issue 
by examining the effect of smoking on life expectancy and survival in a 
large electronic healthcare database of patients receiving secondary mental 
healthcare in South East London.
Methods: Data on all patients with a diagnosis of  schizophrenia, 
schizoaffective disorder or bipolar affective disorder from 1st January 
2007 to 31st December 2018 was obtained. Smoking status was deter-
mined using unstructured text data extracted from electronic health 
records. Chiang’s method of  abridged life tables was used to calculate 
estimates of  life expectancy at birth according to gender and most com-
monly recorded smoking status. Cox proportional hazards models were 
used to estimate mortality risk and adjusted for a broad range of  demo-
graphic and clinical variables.
Results: 21,588 patients were included in the study of  which 20,155 
(93.4%) were classified as either smokers (16,717 [77.4%]) or non-smokers 
(3,438 (15.9%]). 2,434 (11.3%) participants died by the end of  the obser-
vation period. In female patients, life expectancy at birth was 67.6 years 
in current smokers (95% CI: 66.4 to 68.8) and 74.9 years in non-smokers 
(95% CI: 72.8 to 77.0). In male patients, life expectancy at birth was 
63.5 years in current smokers (95% CI: 62.5 to 64.5) and 68.5 years in 
non-smokers (95% CI: 64.4 to 72.6). Adjusted survival models showed 
that current smoking was associated with an increased risk of  death, in 
both females (aHR = 1.42; 95% CI: 1.21–1.66) and males (aHR = 1.49; 
95% CI: 1.25–1.79).
Discussion: Smoking may account for a substantial proportion of the 
reduced life expectancy in patients with psychotic disorders. Interventions 
to reduce tobacco smoking in patients with psychosis may therefore im-
prove life expectancy in this group.
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Background: Substance-induced psychosis is an under-researched phenomenon, 
and little is known about its etiology (other than exposure to substances) and 
long-term prognosis. In this presentation, we aim to present results from two 
recent studies, one of which was recently published and the other is currently in 
the process of being analyzed. The first study investigates rates and predictors 
of conversion from substance-induced psychosis; the second study investigates 
the association between severe infections and substance-induced psychosis, in-
cluding the contribution of infections on conversion to schizophrenia.
Methods: Both studies utilized the nationwide Danish registers.
In study 1, we included all people diagnosed with substance-induced psy-
chosis from 1994 to 2014 (n=6,788). These were followed using the Kaplan-
Meier method and Cox proportional hazards regression to estimate rates 
and predictors of conversion to schizophrenia or bipolar disorder.
In study 2, we included the entire Danish population born since 1981 
(n=2,256,779). These were followed in Cox proportional hazards regression 
models, linking hospital-requiring infections as time-varying covariates to de-
velopment of substance-induced psychosis. In further analyses, we followed 
those who had developed substance-induced psychosis to determine whether 
infections would influence the risk of converting to schizophrenia.
Results: Study 1: Overall, 32.2% (95% CI 29.7–34.9) of patients with a 
substance-induced psychosis converted to either bipolar or schizophrenia-
spectrum disorders. The highest conversion rate was found for cannabis-
induced psychosis, with 47.4% (95% CI 42.7–52.3) converting to either 
schizophrenia or bipolar disorder. Young age was associated with a higher 
risk of converting to schizophrenia. Self-harm was significantly linked to a 
higher risk of converting to both schizophrenia and bipolar disorder.
Study 2: Infections increased the risk of substance-induced psychosis (HR=1.30, 
95% CI 1.22–1.39) in the fully adjusted model. Hepatitis was the infection most 
strongly associated with substance-induced psychosis, at HR=3.42 (95% CI 
2.47–4.74). Different sites of infections showed associations with different types 
of substance-induced psychosis. Finally, hepatitis increased the risk of conver-
sion to schizophrenia with HR=1.87 (95% CI 1.07–3.26).
Discussion: Substance-induced psychosis is strongly associated with the de-
velopment of severe mental illness, and a long follow-up period is needed 
to identify the majority of cases. Infections appear to play a role in the 
etiology of substance-induced psychosis which is very similar to the role 
infections play in the etiology of schizophrenia. This lends strong support 
to the existence of an immune-related component to psychosis in general, 
and not just to schizophrenia.
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